RRM2 and pachyonychia congenita: Treatment with DNMTi and HDACi restores miR‐193b expression and the inhibition of FOXM1 and RRM2 and may be a future strategy for treatment of patients with PC who harbor a hypermethylated miR‐193b promoter.